Ratings Healwell AI Inc.

Equities

AIDX

CA42249X1006

Market Closed - Toronto S.E. Other stock markets 16:15:17 2024-05-03 EDT			5-day change	1st Jan Change
1.5 ^CAD	-5.66%		-2.60%	+100.00%

05-02	WELL Health Technologies Launches Upgraded Version of AI-Powered Physician Co-Pilot Tool	MT
04-04	HEALWELL AI Unit Pentavere Publishes Paper Validating Use of Generative AI to Identify Rare Lung Cancer Patients	MT

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Over the last twelve months, the sales forecast has been frequently revised upwards.
Sales forecast by analysts have been recently revised upwards.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
Analysts covering this company mostly recommend stock overweighting or purchase.
The opinion of analysts covering the stock has improved over the past four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
HEALWELL AI INC.	+100.00%	125M	-	-
AIER EYE HOSPITAL GROUP CO., LTD.	-18.46%	16.57B		B+
BANGKOK DUSIT MEDICAL SERVICES	+4.50%	12.51B		B
IHH HEALTHCARE	+4.31%	11.69B		B+
APOLLO HOSPITALS ENTERPRISE LIMITED	+5.36%	10.36B		B+
ENCOMPASS HEALTH CORPORATION	+24.72%	8.38B		B
RAMSAY HEALTH CARE LIMITED	-2.64%	7.75B		A-
MOUWASAT MEDICAL SERVICES COMPANY	+19.32%	7.16B		D
THE ENSIGN GROUP, INC.	+4.17%	6.6B		B-
GLOBAL HEALTH LIMITED	+46.90%	4.54B		-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes